|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM315861657 |
| 003 |
DE-627 |
| 005 |
20240725232219.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202002440
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1481.xml
|
| 035 |
|
|
|a (DE-627)NLM315861657
|
| 035 |
|
|
|a (NLM)33015883
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Nam, Gi-Hoon
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Emerging Prospects of Exosomes for Cancer Treatment
|b From Conventional Therapy to Immunotherapy
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 24.07.2024
|
| 500 |
|
|
|a Date Revised 24.07.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2020 The Authors. Published by Wiley-VCH GmbH.
|
| 520 |
|
|
|a Exosomes are a class of extracellular vesicles of around 100 nm in diameter that are secreted by most cells and contain various bioactive molecules reflecting their cellular origin and mediate intercellular communication. Studies of these exosomal features in tumor pathogenesis have led to the development of therapeutic and diagnostic approaches using exosomes for cancer therapy. Exosomes have many advantages for conveying therapeutic agents such as small interfering RNAs, microRNAs, membrane-associated proteins, and chemotherapeutic compounds; thus, they are considered a prime candidate as a delivery tool for cancer treatment. Since exosomes also provide an optimal microenvironment for the effective function of immunomodulatory factors, exosomes harboring bioactive molecules have been bioengineered as cancer immunotherapies that can effectively activate each stage of the cancer immunity cycle to successfully elicit cancer-specific immunity. This review discusses the advantages of exosomes for treating cancer and the challenges that must be overcome for their successful clinical development
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a cancer therapeutics
|
| 650 |
|
4 |
|a characterization and clinical-grade exosomes
|
| 650 |
|
4 |
|a exosomes
|
| 650 |
|
4 |
|a extracellular vesicles
|
| 650 |
|
4 |
|a immunotherapy
|
| 700 |
1 |
|
|a Choi, Yoonjeong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Gi Beom
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Seohyun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Seong A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, In-San
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 32(2020), 51 vom: 01. Dez., Seite e2002440
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:32
|g year:2020
|g number:51
|g day:01
|g month:12
|g pages:e2002440
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202002440
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 32
|j 2020
|e 51
|b 01
|c 12
|h e2002440
|